MAPT and Alzheimer disease: First, due to the only recent availability of tau-PET, the sample size of atypical AD subjects was relatively small (n = 30); although others have presented longitudinal tau-PET findings on similar sample sizes (Harrison et al., 2018; Jack et al., 2018).